We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

This study is currently recruiting participants.
Verified October 2017 by Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
First Posted: May 23, 2011
Last Update Posted: November 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Bristol-Myers Squibb
May 19, 2011
May 23, 2011
November 1, 2017
January 31, 2013
December 31, 2029   (Final data collection date for primary outcome measure)
  • Incidence rate of serious infections [ Time Frame: 10 years ]
  • Incidence rate of malignancies [ Time Frame: 10 years ]
  • Incidence rate of autoimmune disorders [ Time Frame: 10 years ]
Same as current
Complete list of historical versions of study NCT01357668 on ClinicalTrials.gov Archive Site
  • Number of serious adverse events [ Time Frame: 10 years ]
  • Number of targeted infections (Epstein-Barr virus, cytomegalovirus, papilloma virus, herpes zoster, tuberculosis and opportunistic infections) [ Time Frame: 10 years ]
Same as current
Not Provided
Not Provided
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Non-Probability Sample
Pediatric rheumatology clinics
Juvenile Idiopathic Arthritis
Not Provided
Patients with JIA who are treated with Abatacept
Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 31, 2029
December 31, 2029   (Final data collection date for primary outcome measure)

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Diagnosis of JIA (any subtype)
  • Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
  • Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial
  • Parent or legally acceptable representative willing to participate in the study and sign the informed consent

Exclusion Criteria:

  • Pregnant or nursing female at the time of enrollment
  • Prior malignancies if the patient has not been malignancy free for at least 5 years.
  • Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study
  • Known poor compliance with clinic visits (based on physician judgment)
Sexes Eligible for Study: All
up to 17 Years   (Child)
Contact: For participation information at a USA site use a phone number below. For Site information outside USA please email: Clinical.Trials@bms.com
Contact: First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time
Austria,   Brazil,   Canada,   Denmark,   France,   Germany,   Greece,   Hungary,   Israel,   Italy,   Latvia,   Mexico,   Netherlands,   Norway,   Peru,   Portugal,   Puerto Rico,   Romania,   Russian Federation,   Saudi Arabia,   Slovakia,   South Africa,   Spain,   United Kingdom,   United States
Argentina,   Belgium
Not Provided
Not Provided
Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
October 2017